Also found in: Medical.
a1PIHuman Alpha 1-Proteinase Inhibitor
References in periodicals archive ?
6 million as well as expenses related to the expansion of the sales force and promotional activities related to the Gamunex IGIV CIDP indication in addition to Prolastin A1PI patient identification.
Two randomized, double-blind, placebo-controlled clinical trials investigated the effect of A1PI therapy on emphysema progression using change in lung density as a measure.
PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) is derived from human plasma and is administered intravenously to raise the levels of A1PI in the blood and lungs.
This increase was largely due to accelerated vesting of stock compensation as well as increased sales and marketing expenses relating to expansion of the sales and marketing activities for the Gamunex IGIV CIDP indication and Prolastin A1PI patient identification.
These data demonstrate that a 120 mg/kg dose of PROLASTIN-C provides closer to physiologic A1PI concentrations than the currently recommended 60 mg/kg dose and confirm the predictable PK profile of augmentation therapy," concluded Dr.
This increase was primarily due to higher Gamunex-C/Gamunex IGIV and Prolastin-C/Prolastin A1PI revenue, lower non-capitalizable project spending, lower inventory impairment provisions, as well as lower unabsorbed infrastructure and start-up costs related to Talecris Plasma Resources, Inc.
TPR), which is Talecris' plasma collection platform, higher Gamunex-C/Gamunex IGIV and Prolastin-C/Prolastin A1PI revenue, as well as lower costs of production primarily driven by production mix associated with the conversion to Prolastin-C.
The annual research grants are part of the Alpha-1 Foundation's ongoing commitment to increase the understanding of alpha-1 antitrypsin deficiency, a genetic disorder in which low levels of the A1PI protein can result in liver damage and emphysema.
Higher revenues from Talecris' principal products Gamunex, Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV) and Prolastin Alpha-1 Proteinase Inhibitor (Human) (Prolastin, Prolastin A1PI, Prolastin-C A1PI) as well as Koate DVI Factor VIII (Human) in the third quarter of 2010 were partially offset by lower sales of albumin, PPF powder and intermediates compared to the third quarter of 2009.
PROLASTIN-C is a more purified and concentrated formulation of A1PI than PROLASTIN and is currently approved in the U.
PROLASTIN-C is a more concentrated version of our PROLASTIN A1PI therapy.
ARALAST is a human alpha-1 proteinase inhibitor (A1PI) indicated for chronic augmentation therapy in patients with hereditary emphysema, a genetic condition caused by a deficiency of A1PI in the lungs.